Matthew K. Fust - Director at Crinetics Pharmaceuticals, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
Director
Issuer Symbol
CRNX on Nasdaq
All Insider Reports
All Insider Reports

Matthew K. Fust - trading volume in the past year for Crinetics Pharmaceuticals, Inc.

Holdings reported by Matthew K. Fust for Crinetics Pharmaceuticals, Inc.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Common Stock 22,836 $1,021,911 $44.75 26 Sep 2025 Direct
Stock Option (Right to Buy) 2,092 26 Sep 2025 Direct Common Stock

Transactions reported by Matthew K. Fust for Crinetics Pharmaceuticals, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.